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PrognosisAbstract Background: Ultrasound guided fine needle aspiration cytology (US-guided
FNAC) can identify microscopic involvement of lymph nodes as in breast cancer and avoid
surgical sentinel node (SN). Its utility in melanoma patients is controversial and subject of this
study.
Methods: Between 2001 and 2010 over 1000 stage I/II consecutive melanoma patients prospec-
tively underwent US-FNAC prior to SN biopsy. All patients underwent lymphoscintigraphy
prior to US-FNAC. The Berlin US morphology criteria: Peripheral perfusion (PP), loss of cen-
tral echoes (LCE) and balloon shaped (BS) were registered. FNAC was performed in case of
presence of any of these factors. SN tumour burden was measured according to the Rotterdam
criteria. All patients underwent SN or lymph node dissection (LND) in case of positive FNAC.
Findings: Mean/median Breslow thickness was 2.58/1.57 mm. Mean/median follow-up was
56/53 months (1–132). SN positivity rate was 21%. US-FNAC Sensitivity was 71% (US only)
and 51% (US-FNAC). Sensitivity of US-FNAC was highest for T4 (76%) and ulcerated mela-
nomas (63%). PP, LCE and BS had sensitivity of 69%, 24% and 24% respectively. Sensitivity ofakulta¨t
el.: +49
C.A. Voit et al. / European Journal of Cancer 50 (2014) 2280–2288 2281US-FNAC increased with increasing SN tumour burden. PP was an early sign of metastasis
(58% in <0.1 mm metastases). Threshold size of a metastasis for FNAC was 0.3 mm. Five-year
survival correlated to US-FNAC status (95% in negative and 59% in positive).
Interpretation: Ultrasound guided FNAC (US-FNAC) according to the Berlin morphology
criteria could correctly identify at least half of all tumour positive sentinel nodes, prior to
the surgical SN procedure. Peripheral perfusion is an early sign of metastasis, which is very
sensitive, but with lower positive predictive value (PPV). It is responsible for the sensitivity
of the procedure. Balloon shape is a sign of advanced metastases, with lower sensitivity, but
high PPV. US-FNAC sensitivity correlated with increasing T-stage, ulceration of the primary
and increasing SN tumour burden. US-FNAC status accurately predicts survival.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Over recent decades the incidence of malignant mela-
noma has been rising throughout Europe, the United
States of America (USA) and Australia [1–4], but mor-
tality has remained virtually unchanged [4].
The most important prognostic factor of early stage
melanomas (stage I/II) is lymph nodal status. There-
fore, adequate staging of these patients is very impor-
tant to be able to determine their prognosis [5,6].
Worldwide, the sentinel node (SN) procedure has been
accepted during the past two decades as the most accu-
rate staging procedure [7]. Sentinel node biopsy (SNB)
is a surgical procedure with a complication rate
between 5% and 10% [8,9]. In the absence of proof that
SNB is associated with a survival benefit alternative
methods to identify positive SNs are being considered.
The diagnostic algorithm of other cancers, such as thy-
roid and breast cancer, already includes pre-operative
ultrasound (US) and fine needle aspiration cytology
(FNAC) and it is conceivable to apply this to
melanomas.
Previously, we have demonstrated that ultrasound
can identify the same node, which is later excised and
considered the sentinel node with an accuracy of 79%
[10]. Another study by our group has demonstrated that
US-FNAC could identify up to 65% of all SN involve-
ment preoperatively [11]. Finally, we have described spe-
cific US patterns, which were used to achieve such a high
sensitivity, the so called Berlin morphology criteria,
which include Peripheral perfusion (PP) as an early sign
of involvement followed by loss of central echo (LCE)
and balloon shape (BS) as signs of advanced involve-
ment [12].
The number of evaluated patients and their mean and
median follow-up have increased significantly. The aim
of the current study was to evaluate our increased expe-
rience with this modern approach comprising the high-
est amount of US-FNAC of SNs and to test its
application as a completion to SNB. This is especially
en vogue with the background of the just now published
results of the MSLT1 trial [13], which is literally a con-
firmation of the results in 2006 and the importance ofthe non-sentinel node status, which can be assessed by
performing completion lymph node dissection (CLND)
after a positive sentinel lymph node biopsy (SLNB)
[14]; or even – as an alternative-directly after a positive
FNAC of the sentinel node.
2. Patient and methods
2.1. Patients
Our prospectively collected database includes all
patients presenting with a histopathologically proven
primary malignant melanoma (at least 1.00 mm Bre-
slow thickness, or if less, at least Clark IV/V, ulcerated
and/or regressed) and who were planned for a sentinel
node procedure at the Department of Dermatology,
Charite´, University Medicine Berlin, Germany. The
institutional ethics review board (ERB) approved the
study and informed consent was obtained from all
patients enrolled. Recruitment for this study started
in 2001, the database now includes over 1500 patients.
For the current analyses, we have censored inclusion
after the first 1000 consecutive patients with sufficient
follow-up (July 2001–November 2010). This cohort
includes the first 400 patients, which have been exam-
ined exclusively by one ultrasonographist (CV) and
whose results have been previously published elsewhere
[11,12].
2.2. Methods
All patients were scheduled for a SN procedure in
either 1 or 2 day protocol. Patients first underwent a
lymphoscintigraphy, which assists the ultrasonographist
to better focus their examination. In the timeslot
between lymphoscintigraphy and surgery, patients were
examined by ultrasound (US) in B-mode and Power
Doppler. US is aimed at clearly depicting the location
of the suspected SN and at clearly stating whether it
seemed to be involved or not. If US depicted a suspi-
cious or malignant SN, FNAC was performed (3–4
repeat FNACs were performed within one procedure)
for verification of the lesion. If a clearly malignant
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patients proceeded to undergo a SN. In the early phase
of the study, all patients with positive FNAC proceeded
to undergo a SN nonetheless (n = 47). During the course
of the study, a change in hospital policy allowed the
surgeon to proceed to an immediate CLND after a
positive FNAC. The decision to change a planned SN
to a CLND was always based on a positive cytology.
US patterns are collected into the prospective database
prior to gathering of the cytology and histopathology
results. If the US does not show any suspicious nodes
or if cytology is negative, the patients proceed to
undergo the scheduled SN as described before [11,12].
Microanatomic location of metastases is evaluated
according to the criteria by Dewar et al. [15]. SN
tumour burden is assessed according to the Rotterdam
criteria for SN tumour burden [16,17]. Final histology
of the SN or LND was considered as the golden
standard.2.3. Ultrasound technique and image analysis
All US examinations were performed using the high-
end device MyLab 70 (ESAOTE, Genova, Italy)
equipped with three transducers (1–18 MHz) (B-mode,
30 pictures per second, colour Doppler, Power Mode).
The lymph node was measured, the pattern was
described and it was classified as benign [b], suspicious
[s] or malignant [m] by an expert ultrasonographist
(C.V.). During the course of the study, two additional
and less extensively trained ultrasonographists were
integrated into the team. An ultrasound was considered
suspicious, when Peripheral perfusion (PP) was present
or if the central echo was wandering towards the rim
[12]. US was considered malignant if there was a total
loss of central echoes (LCE) or if the lymph node was
enlarged and balloon shaped (BS) [12]. If none of these
morphological criteria were present, the lymph node was
considered benign [12]. Details of the ultrasound mor-
phology criteria have been described [12].
Of the 1000 patients, patients’ images have been
saved as jpg.data and were analysed by two experts
using a computerised workstation (ESAOTE, Genova,
Italy). Nodal size was calculated as described previously
[12].2.4. Fine needle aspiration in detail
FNAC was performed with a hand-held Binder-valve
as described in detail elsewhere [18]. The fine needle for
superficial lymph nodes has a diameter of approximately
0.4 mm (26G), especially for small targets. A smear is
considered technically efficient, if it contained approxi-
mately 100 cells.
Cytologic results were reported to the surgeons and it
was left to their discretion how to proceed with surgery,either SN or LND. If the US did not show any suspi-
cious nodes or if the cytology was negative, the patients
proceeded to undergo the scheduled SN.2.5. Histopathological evaluation of excised SN
In brief, lymph nodes were fixed for 24 h in buffered
formalin. After fixation they were cut in half through
the hilum and its longest dimension and embedded in
paraffin. In rare cases, exceptionally large nodes were
sectioned parallel to the first cut in order to fit in the
blocks. Five serial step sections of 4 lm each were cut
from each face of the lymph node, and staining with
H&E, S100 and HMB-45 was performed. Microanatomic
location of the metastases and SN tumour burden were
assessed according to the Dewar and Rotterdam criteria,
respectively [15,16].2.6. Statistics
To assess the diagnostic value of individual and com-
binations of US patterns for involved sentinel nodes,
sensitivity and specificity of those patterns as well as
positive or negative predictive values were calculated.
Associations were tested with Pearson’s chi square test.
Disease-free survival (DFS) and Melanoma specific
survival (MSS) were calculated from SN date until death
or censored at the date of last known follow-up, if no
events had taken place. Univariate analyses of survival
were performed using the Kaplan–Meier method and
the log-rank test. Multivariate analyses to determine
the prognostic value of covariates regarding survival
were performed using the Cox’s proportional hazard
model. Statistical analyses were all performed with
Stata, version 11.0 (Stata Corporation, College
Station, Texas, USA). P values of less than 0.05 were
considered as significant.3. Results
Baseline characteristics of all 1000 patients are
described in Table 1. Mean and median age was 59
and 62 years, respectively (range 15–94 years). Mean
and median Breslow thickness was 2.58/1.57 mm
(0.2–44 mm). Ulceration was present in 24% of primary
melanomas. In total 208 patients (21%) had positive lymph
node disease on histology, either after positive SN
(n = 165, 17% of total, 79% of all lymph node diseases)
or directly proceeded to LND (after positive US-FNAC)
in 43 cases (4% of total, 21% of all lymph node diseases).
The chance for lymph nodal involvement increased with
increasing T-stage; 5% (15/288) for T1, 12% (37/308) for
T2, 32% (73/231) for T3 and 48% (83/173) for T4,
respectively (P < 0.001).
Mean and median follow-up of the total patient
population was 56 and 53 months, respectively (range
Table 1
Baseline patient, tumour and follow-up characteristics of all 1000 patients.
Characteristic N (%) Characteristic N (%)
Gender Sentinel nodes (SNs)s removed
Male 567 (57%) Mean/median (range) 1.72/1 (1–13)
Female 433 (43%) SN result
Histological subtype Negative 792
79%
Superficial soreading melanoma
(SSM)
595 (60%) Positive 208
21%
Nodular melanoma (NM) 242 (24%) Direct LND (after pos FNAC) 43 (4%)
43/208 (21%)
Lentigo maligna melanoma (LMM) 37 (4%) SN tumour burden according to Rotterdam criteria
Acrolentigous melanoma (ALM) 44 (4%) 6 0.1 mm 30 (#%)
30/208 (14%)
Unknown 82 (8%) 0.1–1.0 mm 62 (6%)
62/208 (30%)
Breslow thickness > 1.0 mm 62 (6%)
62/208 (30%)
Mean/median (range) 2.58/1.57 mm (0.2–44 mm) LND/unknown 54 (5%)
54/208 (26%)
T1 (6 1.00 mm) 288 (29%) Peripheral perfusion
T2 (1.01–2.00 mm) 308 (31%) Absent 663 (66%)
T3 (2.01–4.00 mm) 231 (23%) Present 273 (27%)
T4 (>4.00 mm) 173 (17%) Unknown 64 (7%)
Ulceration Loss of central echo (LCE)
Absent 758 (76%) Central echo present (normal) 791 (79%)
Present 242 (24%) Wandering to rim 97 (10%)
Regression Lost 66 (6%)
Absent 633 (63%) Unknown 46 (5%)
Present 300 (30%) Balloon shape (BS)
Unknown 67 (7%) Absent 881 (88%)
Clark level Present 53 (5%)
II 32 (3%) Unknown 66 (7%)
III 341 (34%) Ultrasound guided fine needle aspiration cytology (US-FNAC) results
IV 554 (56%) Not performed & negative/negative 892/342
89%/34%
V 54 (6%) Positive 98 (10%)
98/342 (26%)
Unknown 13 (1%)
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recurrences and 81 melanoma related deaths (8%) dur-
ing this follow-up.
The sensitivity of US alone was 71%. Sensitivity of
US-FNAC (positive FNAC and/or clearly malignant
US) and different subgroups are described in Table 2.
The general combination of US-FNAC yielded a sensi-
tivity of 51%, with a specificity of 99%, a PPV of 99%
and a negative predictive value (NPV) of 89%
(P < 0.001). This means that 72% of lesions correctly
identified by ultrasound, could be confirmed by a posi-
tive FNAC and 28% could not.
Sensitivity of US-FNAC was highest for T4 tumours
(76%) (P < 0.001), ulcerated (63%) (P < 0.001) and
Peripheral perfusion (69%) (P < 0.001). PPV was highest
for balloon shaped (92%) when compared to PP (51%)
or LCE (73%) (P < 0.001). There was one patient
with a false positive FNAC, based on cytology thateventually turned out to correspond to a negative SN.
However, this patient returned with a lymph node
relapse 1 year later.
FNAC was performed in 342/1000 patients (34%).
This was in 172/416 (41.3%) of extremity (arm or leg)mel-
anomas, 139/471 (29.5%) of trunkmelanomas and 31/113
(27.4%) of head & neck melanomas, respectively. In 98/
342 patients the FNAC was positive (26%). Thus, 1:4
patients, who had a suspicious or malignant US, had a
positive FNAC. Ten patients (n = 10) with clearly malig-
nant US morphology did not undergo FNAC, because
there was no time between US and the SN procedure.
Together we consider 108 patients (98 FNAC positive
and 10 US clearly malignant) as US-FNAC positive.
Another sixteen (n = 16) patients with a merely
suspicious ultrasound, did not undergo a FNAC due
to the same above mentioned reason (total 3%). These
cases were treated as FNAC negative. The majority of
Table 2
Sensitivity, specificity, positive predictive values and negative predic-
tive values for ultrasound guided fine needle aspiration cytology (US-
FNAC) per T-stage, ulceration, separate morphology criterion and
US-FNAC combination.
Sensitivity Specificity PPV NPV
T-stage
T1 40% 100% 100% 97%
T2 24% 99% 90% 91%
T3 40% 100% 100% 78%
T4 76% 100% 100% 82%
Ulceration
Absent 43% 99% 98% 90%
Present 63% 100% 100% 83%
Ultrasound morphology criteria
Peripheral perfusion (PP) 69% 82% 51% 91%
Echo wandering to rim 23% 91% 47% 86%
Loss of central echo (LCE) 24% 91% 73% 86%
LCE & wandering to rim 46% 91% 58% 86%
Balloon shape (BS) 24% 99% 92% 83%
US-FNAC total 51% 99% 99% 89%
Table 3
Ultrasound guided fine needle aspiration cytology (US-FNAC) per
sentinel node (SN) tumour burden.
SN
neg
60.1 mm 0.1–1.0 mm >1.0 mm LND/
unknown
US-FNAC
neg
99% 83% 76% 39% 9%
US-FNAC
pos
1% 17% 24% 61% 91%
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Fig. 1. Melanoma specific survival (A) and disease-free survival (B)
according to ultrasound guided fine needle aspiration cytology (US-
FNAC) status.
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need to undergo a FNAC in this study (Fig. 1S).
Of the 658 patients, who had a benign US or did not
have time to undergo a FNAC, 64 patients (10%) had a
positive SN (False Negatives), whereas in the group of
patients with a suspicious or malignant US result and
negative FNAC, the SN was positive in 56/253 cases
(22%). Thus the chance for a positive SN in the group
of patients without FNAC or negative FNAC results
was twice as high in case of a suspicious or malignant
US compared to a benign US result (chance twice as
high for False Negative).
The correct detection by US-FNAC increased with
increasing SN tumour burden. 17% of patients with
SN tumour burden <0.1 mm were detected by US-
FNAC compared to 24% in lesion of 0.1–1.0 mm and
61% of lesions >1.0 mm. Detection was 91% in patients
who proceeded directly to LND or had unknown SN
tumour burden (Table 3). The detection limit (smallest
diameter of SN metastasis) for a positive FNAC was
0.3 mm.
5-Year Kaplan–Meier estimated melanoma specific
survival (MSS) was 95% for US-FNAC negative
patients, compared to 59% for US-FNAC positivepatients, respectively (P < 0.001) (Fig. 1A). The corre-
sponding Kaplan–Meier estimated 5-year disease-free
survival (DFS) rates were 84% for US-FNAC negative
patients versus 33% for US-FNAC positive patients
(P < 0.001) (Fig. 1B).
The 5-year Kaplan–Meier estimated MSS with
negative Berlin morphology criteria (no malignant or
suspicious ultrasound findings) was 96% versus 89%
for Peripheral perfusion (PP) only or central echo
wandering to the rim (P < 0.001) (Fig. 2A). Balloon
shape (BS) or complete loss of central echo (LCE)
yielded a 59% 5-year Kaplan–Meier estimated MSS
(P < 0.001) (Fig. 2A). Corresponding Kaplan–Meier
estimated 5-year DFS was 85% for negative patients
versus 74% for PP or central echo wandering to the
rim (P < 0.001) and 36% for BS and/or LCE
(P < 0.001) (Fig. 2B).
5-Year Kaplan–Meier estimated MSS per SN tumour
burden was 96% for SN negative patients versus 100%
for patients with metastases <0.1 mm in maximum
diameter according to the Rotterdam criteria (n.s.)
(Fig. 3A). Patients with metastases 0.1–1.0 mm had a
73% (P < 0.001) 5-year Kaplan–Meier estimated MSS,
C.A. Voit et al. / European Journal of Cancer 50 (2014) 2280–2288 2285patients with lesions >1.0 mm had a 68% (P < 0.001)
5-year MSS and patients with a LND or unknown SN
tumour burden had a 5-year MSS of 57% (P < 0.001)
(Fig. 3A). Corresponding Kaplan–Meier estimated 5-year
DFS rates were 87% for SN negative patients compared
to 83% for patients with <0.1 mm lesions (P = 0.45)
versus 49% in patients with lesions 0.1–1.0 mm
(P < 0.001) versus 37% for patients with lesions >1.0 mm
(P < 0.001) versus 33% for LND or unknown SN
tumour burden patients (P < 0.001) (Fig. 3B).4. Discussion
Diagnosis of lymph node metastases at the time of
SNB has several potential benefits, including more accu-
rate prognostic information, enhanced nodal control
and disease-free survival, and improvement in overall
survival. However, there is uniformity in agreement that
SNB yields the first two benefits, but improvement in
overall survival has never been conclusively demon-
strated [19]. This present study showed that ultrasound0.00
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Fig. 2. Melanoma specific survival (A) and disease-free survival
(B) according to Berlin ultrasound morphology criteria.alone is able to identify up to 71% of SN metastases pre-
operatively. FNAC confirmation leads to a correct
detection rate of 51% of involved sentinel nodes, prior
to their surgical removal [11,12]. Sensitivity is higher
for subgroups of patients with a priori risk factors for
nodal involvement, such as high Breslow thickness
(T4) or ulceration of the primary, with sensitivity
of 76% and 61%, respectively. Likewise, the volume
of SN tumour burden also affected the sensitivity of
US-FNAC, with sensitivity of 17% in 60.1 mm
metastases versus 61% in metastases >1.0 mm in maxi-
mum diameter.
Peripheral perfusion (PP) had a high sensitivity (69%)
and was potentially capable of detecting a high propor-
tion of metastases, including small and early metastases,
but had a low PPV (51%) and relatively low specificity
(81%).
Balloon shape (BS) and loss of central echo (LCE)
had a low sensitivity (25%), but high PPV (92%). This
means that it detects only relatively few metastases0.00
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Fig. 3. Melanoma specific survival (A) and disease-free survival
(B) according to sentinel node (SN) tumour burden according to the
Rotterdam criteria.
Fig. 4. Diagnostic (staging) algorithm.
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size and do not present with these late patterns), but if
these criteria are seen, the chance that the lesion is
malignant is very high, and consequently, these criteria
correlate to larger (late) metastases.
Sensitivity is lower than our previously reported expe-
rience of the first 400 patients, which had demonstrated
65% sensitivity [11,12]. The sensitivity declined for the
general combination of US-FNAC, but also for all
subgroups of morphological criteria. This can be
explained by the fact the US-FNAC is operator depen-
dent and that all 400 procedures were performed by the
senior ultrasonographist (CV), whereas the next 600
were performed by two further examiners. The results
vary and the learning curves differ (results not shown).
Nevertheless, a 51% sensitivity can potentially spare
10% of all melanoma patients undergoing a SN proce-
dure this unnecessary procedure and obvously can spare
half of positive SN patients this unnecessary procedure.The SN procedure is a minimally invasive staging proce-
dure, which does not have the potential high rates of
major and/or chronic complications as a CLND, but it
is a surgical procedure with potential morbidity none-
theless in contrast to FNAC, which is almost never asso-
ciated with any morbidity. Wound infections, seromas,
bleeding and even in incidental case chronic lymph
oedema have been described [7,20–22]. Also the addi-
tional anaesthesia and costs could potentially be spared.
Our group previously calculated that serial US-FNAC
could potentially save up to 55% of the costs compared
to surgical SN staging in these patients [23].
When compared to the literature, the sensitivity in
our hands (51%) is significantly higher than previously
reported rates, which differ from 4% to 39% [24–29].
In these relatively small series, Starritt et al. achieved a
sensitivity of 21% (7/33), van Rijk et al. achieved 34%
(12/37) and Rossi et al. achieved a rate of 39%
(12/31). A recent small study by Hinz et al. demonstrated
C.A. Voit et al. / European Journal of Cancer 50 (2014) 2280–2288 2287that high-resolution ultrasound (HRUS) yielded a
sensitivity of 12% (2/17) [28]. Chai et al. demonstrated
a sensitivity of 34%, but only 10 patients (3.4%) could
undergo US-FNAC prior to the surgical SN in their
study [29]. The preliminary results of one larger series,
pre-SN US-FNAC in the MSLT-2 study, reported
sensitivity of merely 4.2% (8/193) [24].
Possible causes for these differences can be sought in
the threshold for performing of a FNAC, which might
be much higher in these studies. If we had performed
a FNAC only in those cases with either BS or LCE
reflecting the later and late signs, the sensitivity would
have been as low as 24%, which is exactly comparable
to these other series.
Regarding survival, a study by Pilko et al. showed
lower SN tumour burden and improved survival for
US negative patients compared to US positive patients,
even in the absence of a positive FNAC [30]. This is in
line with our observation that US negative (no suspi-
cious or malignant morphology criteria) patients have
the best prognosis compared to PP only with a slightly
decreased survival and a low survival rate for BS and/
or LCE (Fig. 2A/B) having in mind that sensitivity of
US was 71% in the present study.
Looking to other types of cancer, ultrasound guided-
FNAC staging is commonly applied as routine staging
in breast and thyroid cancers [31–33]. In comparison,
a meta-analysis by Alvarez et al. described ultrasound
sensitivity for non-palpable lymph node metastases in
breast cancer ranging from 48.8% to 87.1% with specific-
ity ranging from 55.6% to 97.3%. When the morphology
of a lymph node was used, the sensitivity ranged from
26.4% to 75.9% with a specificity of 88.4% to 98.1%
[34,35]. These rates are considered sufficient to apply
the modality to the pre-operative work-up for breast
cancer patients.
There is an ongoing discussion, whether patients with
a minimal tumour load in the SN do really benefit from
subsequent CLND. To date several studies like MSLT-2
and the EORTC 1208 (Minitub) are being performed to
investigate whether CLND can be spared in these
patients [36,37].
We envision that ultrasound guided FNAC can play
a role in the future diagnostic algorithm of primary stage
I/II melanoma patients (Fig. 4). As an addendum to the
SLNB, US-guided FNAC is a pre-screening to enable a
one-time setting, so that US-guided FNAC positive
patients directly undergo completion lymph node dissec-
tion (CLND). Thus it can give early staging information
of non-SLN involvement. Since Ultrasound or Ultra-
sound-guided FNAC negative patients will anyway
undergo SLNB, no patient will be overlooked. More-
over, SLNB is an operation with concomitant morbidity
and a false negative rate between 9% and 21% [38].
To validate our results in amulticenter, multi-observer
fashion, we have undertaken our first EORTCMelanomaGroup sentinel node ultrasound course in 2012 to educate
others in Berlin Morphology criteria.
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